百奧賽圖-B(02315.HK)預計9月1日掛牌上市 引入維科控股等多家基石
格隆匯8月19日丨百奧賽圖-B(02315.HK)發佈公吿,公司擬全球發售2175.85萬股股份,其中香港發售股份217.6萬股,國際發售股份1958.25萬股,另有15%超額配股權;2022年8月19日至8月24日招股;發售價將為每股發售股份25.22港元,每手買賣單位500股,入場費約12737港元;中金公司及高盛為聯席保薦人;預期股份將於2022年9月1日於聯交所主板掛牌上市。
集團於2009年成立,是生物製藥及臨牀前研究服務創收公司。集團有YH003及YH001兩種核心產品以及10種其他管線候選產品。YH003是一種重組人源化激動性抗細胞分化簇40(CD40)免疫球蛋白G2(IgG2)單克隆抗體,YH001是一種重組人源化抗CTLA-4(在T細胞上組成型表達的蛋白質受體,作用機制為作為免疫檢查點起作用,並下調免疫應答)免疫球蛋白G1(IgG1)單克隆抗體。集團的核心產品YH003主要開發用於胰腺導管腺癌、黑色素瘤及其他晚期實體瘤。集團的其他核心產品YH001主要開發用於肝細胞癌(HCC)、非小細胞肺癌 (NSCLC)及其他實體瘤。大部分臨牀階段候選藥物(包括核心產品)均發展成聯合療法。
集團已訂立基石投資協議,據此,基石投資者已同意在若干條件規限下按發售價認購以合共4980萬美元(或約3.904億港元)可購買的一定數目的發售股份。假設發售價為25.22港元,基石投資者將予認購的發售股份總數為1547.85萬股。基石投資者包括維科(香港)經貿有限公司(由維科控股全資擁有)、榮昌生物(688331.SH)、三金國際股份有限公司(桂林三金(002275.SZ)全資擁有)、QuantumPharm Inc.(晶泰科技的控股公司)、及北京興星股權投資合夥企業(有限合夥)。
集團估計,來自全球發售的總所得款項淨額(假設未行使超額配股權,發售價為每股25.22港元)將為約4.711億港元。集團目前計劃將該所得款項淨額約35%用於為YH003的研發提供資金;約35%將用於為YH001的臨牀研發提供資金;約15%用於根據集團的千鼠萬抗計劃為抗體藥物發現及開發提供資金;約10%用於集團其他管線產品的臨牀前及臨牀開發;及約5%將用作營運資金及其他一般公司用途。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.